P3 Health Partners Reports 4% Revenue Decline to $373.2 Million, Adjusted EBITDA Loss of $22.2 Million in Q1 2025

Reuters
05-16
P3 Health Partners Reports 4% Revenue Decline to $373.2 Million, Adjusted EBITDA Loss of $22.2 Million in Q1 2025

P3 Health Partners Inc. reported its financial results for the first quarter of 2025, showing a total revenue of $373.2 million, a decrease of 4% compared to $388.5 million in the same quarter of the previous year. The medical margin for the quarter was $17.2 million, significantly down from $36.6 million in the first quarter of the prior year, with the medical margin PMPM at $49 compared to $96 previously. This decrease included a negative $23 million net impact from prior year claims related to a single payer. The company also reported an Adjusted EBITDA loss of $22.2 million, compared to a loss of $19.8 million in the previous year's first quarter. The Adjusted EBITDA loss PMPM was $64, up from $52 in the prior year, which included a negative $9 million net impact from prior year claims and retroactive adjustments. P3 Health Partners affirmed its 2025 guidance, noting that its physician-led care enablement model is contributing to improvements in quality measures and cost management, with three out of four markets achieving breakeven or better in the first quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. P3 Health Partners Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-025928), on May 15, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10